306 related articles for article (PubMed ID: 10474520)
1. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.
Cohen I; Perel E; Flex D; Tepper R; Altaras MM; Cordoba M; Beyth Y
J Clin Pathol; 1999 Apr; 52(4):278-82. PubMed ID: 10474520
[TBL] [Abstract][Full Text] [Related]
2. [Tamoxifen and endometrial pathology].
Negoiţă M; Terinte C; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468
[TBL] [Abstract][Full Text] [Related]
3. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.
Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR
AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
Lee M; Piao J; Jeon MJ
Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
[TBL] [Abstract][Full Text] [Related]
5. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
[TBL] [Abstract][Full Text] [Related]
6. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
7. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen.
Bertelli G; Valenzano M; Costantini S; Rissone R; Angiolini C; Signorini A; Gustavino C
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):275-7. PubMed ID: 10985880
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal endometrial pathologies with tamoxifen treatment: comparison between hysteroscopic and hysterectomy findings.
Cohen I; Azaria R; Aviram R; Bernheim J; Tepper R; Cordoba M; Beyth Y
Gynecol Obstet Invest; 1999; 48(3):187-92. PubMed ID: 10545744
[TBL] [Abstract][Full Text] [Related]
9. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I
Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946
[TBL] [Abstract][Full Text] [Related]
10. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow.
Develioğlu OH; Omak M; Bilgin T; Esmer A; Tüfekçi M
Gynecol Oncol; 2004 May; 93(2):328-35. PubMed ID: 15099941
[TBL] [Abstract][Full Text] [Related]
11. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study.
Achiron R; Lipitz S; Sivan E; Goldenberg M; Horovitz A; Frenkel Y; Mashiach S
Ultrasound Obstet Gynecol; 1995 Aug; 6(2):116-20. PubMed ID: 8535913
[TBL] [Abstract][Full Text] [Related]
12. Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen.
Ozşener S; Ozaran A; Itil I; Dikmen Y
Eur J Gynaecol Oncol; 1998; 19(6):580-3. PubMed ID: 10215447
[TBL] [Abstract][Full Text] [Related]
13. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
14. The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen.
Kazerooni T; Ghaffarpasand F; Mosalaei A; Kazerooni Y
Med Princ Pract; 2010; 19(3):222-7. PubMed ID: 20357508
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy.
McGonigle KF; Shaw SL; Vasilev SA; Odom-Maryon T; Roy S; Simpson JF
Am J Obstet Gynecol; 1998 Jun; 178(6):1145-50. PubMed ID: 9662294
[TBL] [Abstract][Full Text] [Related]
16. Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patients treated with tamoxifen.
Cohen I; Altaras MM; Shapira J; Tepper R; Cordoba M; Figer A; Zalel Y; Dror Y; Beyth Y
Gynecol Obstet Invest; 1997; 43(1):60-3. PubMed ID: 9015703
[TBL] [Abstract][Full Text] [Related]
17. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen.
Marconi D; Exacoustos C; Cangi B; Perroni A; Zupi E; Valli E; Romanini C
J Am Assoc Gynecol Laparosc; 1997 May; 4(3):331-9. PubMed ID: 9154782
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
19. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
20. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen.
Marchesoni D; Driul L; Fabiani G; Di Loreto C; Cataldi P; Mozzanega B
Int J Gynaecol Obstet; 2001 Dec; 75(3):257-62. PubMed ID: 11728486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
